What I wish I knew about Multiple Myeloma treatments 25 years later...

Download the FREE ebook "Beating Myeloma: If I Knew Then What I Know Now" and arm yourself with the information about autologous stem cell transplantation, treatment options, and side effects that I wish I had known about when I began treatment.

Cytogenetic Testing- Relapsed/Refractory Multiple Myeloma- Options

Share Button

“Patients with certain kinds of relapsed or refractory multiple myeloma can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab)…

If your multiple myeloma has been diagnosed as “relapsed and refractory” it means that you have probably undergone many different conventional MM therapies and have relapsed. You may be open to different types of options.

The good news is that the trial discussed below offers hope. The bad news is that there is a lot that you just don’t know. You don’t really know the short, long-term and late stage side effects than can occur. You don’t know what sort of remission you can achieve. But as a MMer you probably have throught about all this before.

While you consider your conventional options you should also consider evidence-based non-conventional therapies as well. I am a long-term MMer and MM Cancer Coach. I have lived in complete remission from my MM since 1999 through a series of evidence-based non-conventional therapies.

Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.

Click here to follow along with the Introduction Guide

Click here to get your FREE First Questions Guide


Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:


Cytogenetics

Cytogenetics is a branch of genetics that is concerned with how the chromosomes relate to cell behaviour, particularly to their behaviour during mitosis and meiosis.[1] Techniques used include karyotyping, analysis of G-banded chromosomes, other cytogenetic banding techniques, as well as molecular cytogenetics such as fluorescent in situ hybridization (FISH) and comparative genomic hybridization (CGH).”

Trial to Assess NY-ESO SPEAR T-cells as Part of a Combo Therapy Against Multiple Myeloma

“Patients with certain kinds of relapsed or refractory multiple myelomas can enroll in a clinical trial assessing a combination of NY-ESO SPEAR T-cells and Keytruda (pembrolizumab)…

To qualify for the study, patients’ tumor cells must express the NY-ESO or LAGE-1 proteins, or both. Expression is the process by which information from a gene is used to create a functional product like a protein…

Keytruda, which targets the PD-1 protein associated with some cancers, has shown promise against multiple myeloma in combination with other therapies. There is preclinical-trial evidence “to support the view that the combination of NY-ESO SPEAR T-cells and anti-PD-1 therapy may lead to meaningful anti-tumor activity,” Amado said…

NY-ESO-1 is a cancer antigen, or molecule that can trigger an immune response against cancer. Researchers have found high levels of its expression in multiple myelomas that carry a bleak prognosis

It tested NYO-ESO spear in a previous Phase 1/2 single-arm clinical trial (NCT01352286) of 25 high-risk or relapsed myeloma patients with few remaining treatment options and low life expectancy. The treatment led to a complete response — or the disappearance of all signs of the cancer — in 70 percent of the patients within three months. Patients had high-dose chemotherapy and a stem cell transplant before receiving the modified T-cells…

 

 

Leave a Comment:

2 comments
Add Your Reply